Neurotrophins play critical roles in the survival, maintenance and death of neurons. In particular, proneurotrophins have been shown to mediate cell death following brain injury induced by status epilepticus (SE) in rats. Previous studies have shown that pilocarpine-induced seizures lead to increased levels of proNGF, which binds to the p75 NTR -sortilin receptor complex to elicit apoptosis. A screen to identify compounds that block proNGF binding and uptake into cells expressing p75 and sortilin identified lithium citrate as a potential inhibitor of proNGF and p75 NTR -mediated cell death. In this study, we demonstrate that low, submicromolar doses of lithium citrate effectively inhibited proNGF-induced cell death in cultured neurons and protected hippocampal neurons following pilocarpine-induced SE in vivo. We analyzed specific mechanisms by which lithium citrate afforded neuroprotection and determined that lithium citrate prevented the association and internalization of the p75 NTR -sortilin receptor complex. Our results demonstrate a novel mechanism by which low-dose treatments of lithium citrate are effective in attenuating p75 NTR -mediated cell death in vitro and in vivo.
Introduction
The neurotrophin growth factors regulate many aspects of neuronal function, including cell survival and death.
Neurotrophins are initially synthesized as precursor proneurotrophins and are cleaved to generate their C-terminal mature forms, which bind to the Trk family of receptor tyrosine kinases to enhance neuronal survival and differentiation (Huang and Reichardt, 2003; Reichardt, 2006) . In contrast, proneurotrophins bind with high affinity to a receptor complex comprised of p75 NTR and sortilin, which can initiate apoptotic signaling (Lee et al., 2001; Nykjaer et al., 2004) . Following injury, proneurotrophins and p75 NTR are upregulated and can play a significant role in promoting neuronal cell death. Previous studies have demonstrated that prolonged severe seizures, induced by either pilocarpine or kainic acid, promote neuronal death in rats mediated by p75 NTR (Troy et al., 2002) . Seizures also elevate levels of proNGF, a potent ligand for the activation of p75 NTR -mediated cell death (Volosin et al., 2008) , and prevent its cleavage by MMP7, leading to increased levels of intact proNGF in the extracellular environment (Le and Friedman, 2012) . ProNGF induces neuronal death by interacting with a receptor complex consisting of p75 NTR and sortilin (Nykjaer et al., 2004; Hempstead, 2009) . Moreover, the two receptors can be recruited to the cell surface by inflammatory cytokines, thereby increasing vulnerability to proNGF after brain injury (Choi and Friedman, 2014) .
Recently, we performed a drug screen to identify compounds that block the binding of proNGF to cells expressing sortilin and p75 NTR , and lithium citrate was among these compounds. Lithium ion can inhibit apoptosis by a variety of different mechanisms (Wada et al., 2005) , including increasing Akt activity, by phosphorylating and inactivating GSK3␤ (Tajes et al., 2009; Pasquali et al., 2010) , and promoting autophagy (Motoi et al., 2014; Del Grosso et al., 2016; Liu et al., 2017) . Chronic treatment with lithium has also been shown to upregulate BDNF expression in the brain (Fukumoto et al., 2001 ) and retina (Wu et al., 2014) , which provides another potential neuroprotective mechanism for lithium ion. However, since the drug screen identified lithium citrate by preventing the binding and uptake of proNGF to its p75 NTR -sortilin receptor complex, another potential target for lithium ion could be in altering this receptor complex.
In a rat experimental model of temporal lobe epilepsy (TLE), status epilepticus (SE) induced by pilocarpine causes a defined pattern of damage in the hippocampus with severe loss of neurons in the CA1 region as well as the hilus/dentate gyrus region (Turski et al., 1984 (Turski et al., , 1989 . Previous studies have demonstrated that much of the seizure-induced neuronal loss is due to the upregulation of proNGF and p75 NTR (Roux et al., 1999; Troy et al., 2002; Volosin et al., 2008) , and blocking proNGF-p75 NTR signaling, using function-blocking polyclonal antibodies to the prodomain of proNGF, attenuates hippocampal cell death following seizures (Volosin et al., 2008; Song et al., 2010) . Therefore, in these studies, we investigated the mechanisms by which lithium citrate affords neuroprotection from proNGF induced cell death, and tested the efficacy of lithium citrate in preventing p75 NTR -mediated cell death following pilocarpine-induced seizures. We demonstrate that low doses of lithium, well below the dose used for the standard lithium-pilocarpine model of epilepsy (Jope et al., 1986) and below the dose needed to phosphorylate GSK3␤ or induce BDNF (Wada et al., 2005) , decreased the association and internalization of the p75 NTR -sortilin receptor complex, and prevented proNGFinduced neuronal apoptosis in culture and in vivo.
Materials and Methods

Alexa Fluor 594 labeling of proNGF
Twenty micrograms of purified human proNGF, prepared in SF9 cells as described (Feng et al., 2010) , was added to 10 l of PBS and 7 l of reconstituted Alexa Fluor 594 (excitation 590 nM, emission 617 nM; Invitrogen) according to the manufacturer's protocol (microscale protein labeling kit A30008) and incubated at room temperature, in the dark, for 15 min. Tris, pH 8.0, was added to obtain a final concentration of 50 mM to quench the labeling reaction. Labeled proNGF was then extensively dialyzed using PBS, pH 7.4, at 4°C in the dark. Alexa Fluor-labeled proNGF was used within 48 h. HT-1080 cells that stably expressed p75 and sortilin (generated as described; Feng et al., 2010) , were cultured in 384 well flat bottom plates (CellBind) for 24 h. Cells were treated with one of 2560 compounds from the SpecPlus Collection (MicroSource Discovery Systems) at a concentration of 10 M, or 20 M neurotensin, or diluent control, using an automated robotics system, followed by addition of 200 nM Alexa Fluor-proNGF. Cells were incubated for 18 h, then rinsed with PBS, and fixed with 4% paraformaldehyde for 10 min, rinsed three times with PBS, and then counterstained using Hoechst at a final concentration of 10 g/ml for 2 h at room temperature. Cells were analyzed for uptake of Alexa Fluor 594-conjugated proNGF using a Discovery 1 automatic fluorescence microscope from Molecular Devices as described previously (Pipalia et al., 2006) .
Images were acquired with a Photometrics Cool Snap HQ camera and analyzed using Metapmorph Discovery 1 image analysis software. To correct for shading, an image was created by averaging all of the images from a plate and smoothing the averaged image with a low pass filter. Thresholding was performed, using a low threshold to include all areas occupied by cells. The outlines of cells were selected, as were the outlines of nuclei, assessed by Hoecht staining. The number of pixels in the area of the cell within two nuclear diameters of the nuclei were calculated, and the average proNGF intensity was calculated as the total intensity above the low threshold/number of pixels above low threshold (modified from Pipalia et al., 2006 
Primary hippocampal neuronal cultures
All animal studies were conducted using the National Institutes of Health guidelines for the ethical treatment of animals with approval of the Rutgers Institutional Animal Care and Facilities Committee.
Rat hippocampi were dissected from embryonic day 18 animals and dissociated as previously described (Friedman, 2010) . Dissociated neurons were then plated on poly-Dlysine (0.1 mg/ml)-coated dishes maintained in serum free media. The media consisted of 1:1 MEM and F12, with glucose (6 mg/ml), insulin (2.5 mg/ml), putrescine (60 M), progesterone (20 nM), transferrin (100 g/ml), selenium (30 nM), penicillin (0.5 U/ml), and streptomycin (0.5 g/ml). Neuronal cultures were maintained in media for 5 d before treatment with proNGF and lithium citrate.
Cell culture treatments and survival assay
Lithium citrate doses in the nanomolar and micromolar ranges did not show toxicity in prescreen testing and was used here at doses ranging from 10 nM to 100 M. Following proNGF (2-5 ng/ml) and lithium citrate treatment, hippocampal neurons were lysed and healthy nuclei were counted using a hemocytometer to assess cell viability (Friedman, 2010) . To distinguish between nuclei of healthy cells and those of dead cells, pyknotic and irregular membrane shapes common to cells dying via apoptosis were assessed and excluded. Cell counts were performed in triplicate.
6-Bromoindirubin-3'-oxime (BIO) was purchased from Sigma and dissolved in DMSO for a stock concentration of 3 mM.
For Western blot analysis, hippocampal neurons plated in six-well dishes (1 ϫ 10 6 cells/well) were treated as indicated, washed in sterile PBS (pH 7.4) and lysed in buffer containing 120 mM Tris, 2% SDS, 10% glycerol and protease inhibitors. Equal amounts of protein were subjected to PAGE, transferred to nitrocellulose membrane and blocked with 5% nonfat milk. Blots were incubated in primary antibodies to GSK3␤, p-GSK3␤, BDNF, and actin overnight. After washing three times with TBST for 15 min each, the blots were incubated with appropriate secondary antibodies for 1 h at room temperature. The membrane was washed three times with TBST before being visualized using either ECL (Pierce) or scanned with the Odyssey infrared imaging system (LI-COR Bioscience). To ensure equal protein levels, blots were stained with Ponceau and reprobed with actin. All analyses were performed at least three times in independent experiments.
Pilocarpine induced seizures
Adult male Sprague Dawley rats (250-350 g) were pretreated with methyl-scopolamine (1 mg/kg, s.c.; Sigma) to prevent peripheral effects 30 min before giving pilocarpine (350-380 mg/kg) to induce SE. One hour following the onset of SE (Racine scale stage 5 behavior), animals were treated with diazepam (10 mg/kg) and phenytoin (50 mg/ kg) to reduce the seizures. Control animals received the same treatments except they received saline instead of pilocarpine. Animals were given Hartmann's solution (130 mM NaCl, 4 mM KCl, 3 mM CaCl, and 28 mM lactate; 1 ml/100 g) daily until they were capable of eating and drinking ad libitum and monitored for 3 d.
To assess the effects of lithium citrate on neuronal death in vivo, animals were treated with lithium citrate (6 mg/kg, s.c.) 30 min before receiving pilocarpine or saline. To assess whether lithium could provide effective neuroprotection if given after the seizures, a different cohort of animals was given lithium citrate after the seizures were stopped with diazepam and phenytoin. In each experiment, animals were designated as controls, pilocarpine, pilocarpine ϩ lithium, and lithium alone. Rats treated with lithium citrate were given injections every 12 h for 3 d to maintain relatively constant levels of lithium (Malhi and Tanious, 2011) . Levels of lithium ion that entered the brain were measured in CSF collected at the time of euthanasia.
Immunohistochemistry
Animals were anesthetized with ketamine/xylazine and perfused transcardially with saline followed by 4% paraformaldehyde. The brains were removed and postfixed in 4% paraformaldehyde for 2 h and cyroprotected in 30% sucrose overnight. Sections (12 m) were cut on a cryostat (Leica) and mounted onto charged slides. Sections were blocked in PBS/5% BSA and permeabilized with PBS/0.3% Triton X-100, and then exposed to primary antibodies overnight at 4°C in PBS/1% BSA. Slides were then washed three times in PBS, exposed to secondary antibodies coupled to different fluorophores at room temperature for 1 h in the dark. Sections were washed again three times, with 4',6'-diamidino-2-phenylindole (DAPI; Sigma; 1:10,000) present in the final wash. Sections were coverslipped with antifading medium (ProLong Gold; Invitrogen) and analyzed by fluorescence microscopy (Nikon). Primary antibodies used are as follows: anti-p75 (1:500; R&D Systems, RRID:AB_2298561) and anti-cleaved caspase-3 (CC3; 1:1000; Cell Signaling Technology, RRID:AB_2069869).
Fluoro-Jade C labeling
The number of dying neurons following pilocarpine induced seizures was assessed by labeling with Fluoro-Jade C (Millipore) according to the manufacturer's protocol. Sections were then immunostained with anti-p75 NTR .
Coimmunoprecipitation and Western blotting
Cultured hippocampal neurons were treated with lithium citrate for 30 min followed by a 30-min treatment with proNGF and compared with neurons treated with proNGF alone, lithium citrate alone and untreated control neurons. Cells were harvested in a buffer containing 0.6 M octylglucoside, 10% Triton X-100, 10ϫ TNE with a phosphatase inhibitor cocktail tablet (Roche). Whole-cell lysates were precleared with protein G-Sepharose beads (Pierce) at 4°C for 60 min. The cleared lysates were incubated overnight at 4°C with ␣-p75 NTR (192 IgG, Millipore) followed by a 2-h incubation at 4°C with protein G-Sepharose beads. Finally, the beads were washed five times with the buffer described above, eluted by boiling in loading buffer for SDS-PAGE. Equal amounts of protein were separated by 8% PAGE, transferred to nitrocellulose membranes, and probed for sortilin (diluted 1:500, BD Sciences) and p75 NTR (diluted 1:500, Cell Signaling). All Western blot analyses were performed at least three times with samples from independent experiments.
For the in vivo experiments, hippocampi were dissected 3 d after the seizures and homogenized in RIPA buffer. Lysates were cleared with protein G-Sepharose and incubated overnight with anti-sortilin (BD Science), followed by a 2-h incubation with protein G-Sepharose beads. Samples were analyzed by Western blotting for p75 NTR (Millipore).
Biotinylation assays
Cell surface receptor biotinylation assays were performed using cultured hippocampal neurons. Cultures were rinsed with PBS and subsequently washed with PBS containing magnesium chloride and calcium chloride. Cultures were then biotinylated with sulfo-NHS-S-S-biotin (Pierce). Cells were rinsed with 100 nM glycine to quench remaining biotin, and were then incubated at 37°C for 10 min in media alone (control) or in media containing proNGF (3 ng/ml), lithium citrate (100 nM), or proNGF ϩ lithium citrate. Remaining cell surface biotin was cleaved with 50 mM glutathione, 75 mM NaCl, 75 mM NaOH, 0.01 g/ml BSA, and 10 mM EDTA, and cells were lysed in RIPA buffer with protease inhibitors. Biotinylated proteins were precipitated with streptavidin beads to pull down internalized receptors, followed by immunoblotting for p75 NTR and sortilin. Each experiment was repeated at least three times.
Quantification and statistical analysis
For quantification of immunostaining analysis, every 8th section throughout the hippocampus was processed for p75 NTR /CC3 double immunocytochemistry. Doublelabeled cells from the hilus and CA1 regions, areas susceptible to pilocarpine-induced damage, were counted on both sides of the hippocampus. Adjacent sections were taken for analysis of p75 NTR /fluorojade double-labeled cells in the hilus and CA1 regions of the hippocampus. The number of labeled cells is expressed as percentage control relative to the number of labeled cells in control brains. Statistical analysis was performed using ANOVA with Tukey's post hoc analysis, and p Ͻ 0.05 was considered significant.
For quantification of immunoprecipitation and biotinylation analysis, bands were quantified densitometrically and are shown as the mean of three independent experiments. Statistical analysis was performed using ANOVA with Tukey's post hoc analysis and p Ͻ 0.05 was considered significant.
Results
Screen to identify inhibitors of proNGF binding and uptake to p75
NTR -sortilin expressing cells We performed a drug screen to identify compounds that blocked the binding and internalization of fluorescentlylabeled (Alexa Fluor) proNGF using cells stably expressing p75 NTR and sortilin. Stable clones of human fibrosarcoma HT-1080 cells expressing p75 NTR , sortilin, or both receptors were generated, and the receptor expression was confirmed by Western blot analysis. Our prior studies using these conditions documented that coexpression of p75 NTR and sortilin led to enhanced uptake of labeled proNGF, as compared to cells expressing comparable levels of p75 NTR or sortilin alone (Feng et al., 2010) . Binding and uptake of Alexa Fluor-proNGF was inhibited by Ͼ90% on concomitant treatment with 10 M neurotension, consistent with prior studies in which neurotensin impaired the crosslinking of proNGF to p75/sortilin complexes, and impaired proNGF-induced apoptosis (Nykjaer et al., 2004) . Compounds from a commercially available library were screened for reduction in proNGF-uptake. Drugs (at 10 M concentration) that exhibited a 66% reduction in uptake, and resulted in Ͼ85% viability as compared to control, were considered potential antagonists. Fifteen compounds which met these criteria, and have been used in humans are listed in Table 1 . Lithium citrate was among the 15 candidate compounds identified, inhibiting proNGF uptake by 66.4% as compared to diluent control, and exhibited no significant toxicity (Ͻ5% cell loss as compared to control). Therefore, lithium citrate was further evaluated using cultured neurons.
Low dose of lithium protects hippocampal neurons from proNGF-induced death in vitro
To analyze mechanisms by which lithium citrate could protect hippocampal neurons from proNGF-induced death, cultured neurons were treated with proNGF with or without lithium citrate pretreatment. A dose-response analysis demonstrated that lithium citrate protected neurons from proNGF-induced death, with the lowest protec- Fifteen compounds were identified from the 2560 screened that that exhibited a 66% reduction in proNGF uptake at 10 M concentration and resulted in Ͼ85% viability as compared to control.
tive dose of 100 nM (Fig. 1A) . Lithium ion is known to be neuroprotective by a variety of mechanisms (Wada et al., 2005; Young, 2009) , including via phosphorylation and inactivation of GSK3␤, therefore we investigated whether the doses at which lithium citrate prevented proNGFinduced death were sufficient to phosphorylate GSK3␤. Interestingly, the lowest protective doses of 100 nM and 1 M were insufficient to phosphorylate GSK3␤ (Fig. 1B) . In addition, a different method of inactivating GSK3␤ using BIO (Meijer et al., 2003) , rather than lithium citrate was unable to protect hippocampal neurons from proNGFinduced apoptosis (not shown). These data indicate that the neuroprotective actions of lithium citrate were not mediated by GSK3␤ phosphorylation and inactivation. Additionally, chronic treatment with lithium has also been shown to upregulate BDNF expression in the brain (Fukumoto et al., 2001 ) and retina (Wu et al., 2014) , which provides another potential neuroprotective mechanism for Figure 1 . Dose-dependent effects of lithium citrate on hippocampal neurons. A, E18 hippocampal neurons were cultured for 5 d and treated overnight with or without proNGF (3 ng/ml) alone or in the presence of different doses of lithium citrate. Cells were then lysed and healthy nuclei of surviving neurons were counted; 100 nM lithium citrate was sufficient to protect neurons from proNGF. B, Dose response for lithium citrate to induce phosphorylation of GSK3␤ in vitro. Cultured hippocampal neurons were treated with the indicated doses of lithium citrate and analyzed by Western blotting for p-GSK3␤. Blots were stripped and reprobed for total GSK3␤. Quantification of four independent experiments is shown. C, Dose response for lithium citrate to induce BDNF expression. Cultured hippocampal neurons were treated with the indicated doses of lithium citrate and analyzed by Western blotting for BDNF. Blots were stripped and reprobed for actin. Quantification of three independent experiments is shown, ‫ء‬ significant at p Ͻ 0.05 by ANOVA.
New Researchlithium. Therefore, we compared the dose of lithium citrate that was required for BDNF induction with the dose that protected hippocampal neurons from proNGF-induced apoptosis. Robust induction of BDNF was observed at 100 M, a dose at least 1000-fold higher than the dose required for protection from proNGF (Fig. 1C) . These data indicate that the protection afforded by lithium citrate was due neither to phosphorylation of GSK3␤ nor to induction of BDNF, and might represent a novel mechanism.
Lithium citrate prevents the association and internalization of the p75 NTR -sortilin receptor complex
The initial identification of lithium citrate as being protective from proNGF-induced apoptosis was based on a screen that blocked binding to the p75 NTR -sortilin receptor complex and subsequent internalization, therefore we assessed whether lithium citrate could act at the level of the membrane receptors to prevent proNGF actions by interfering with the formation of the p75 NTR -sortilin receptor complex, or internalization of the receptors. Cultured hippocampal neurons were treated for 30 min with proNGF with or without a 30-min pretreatment with 100 nM lithium citrate and compared to untreated neurons or treatment with lithium citrate alone. Cell lysates were immunoprecipitated with anti-p75 NTR , probed for sortilin and reprobed for p75 NTR . Levels of p75 NTR were increased by proNGF treatment, which was not affected by the lithium citrate pretreatment, however the amount of coimmunoprecipitated sortilin was significantly reduced by the lithium citrate pretreatment (Fig. 2) , suggesting that lithium citrate attenuated the association between sortilin and p75 NTR . Treatment with proNGF elicits internalization of the p75 NTR -sortilin receptor complex, therefore we also investigated whether lithium citrate treatment could affect receptor internalization. Cell surface biotinylation experiments investigated the internalization of the receptors after proNGF treatment. Cultured hippocampal neurons were biotinylated and then incubated with proNGF for 10 min with or without pretreatment with lithium citrate. Surface biotin was then stripped off and streptavidin was used to pull down internal- ized biotinylated proteins, which were probed for p75 NTR (Fig. 3A,D) and sortilin (Fig. 3A,C) . Pretreatment with 100 nM lithium citrate significantly reduced the internalization of sortilin and p75 NTR (Fig. 3) . Thus, the low dose of lithium citrate (100 nM) that was protective from proNGF-induced neuronal death attenuated the association and internalization of the p75 NTR -sortilin receptor complex.
Lithium citrate protects hippocampal neurons from pilocarpine-induced neuronal loss
Pilocarpine-induced seizures elicit neuronal apoptosis in the CA1 and hilus regions of the rat hippocampus at least in part by increasing the level of extracellular proNGF and activating p75 NTR apoptotic signaling (Troy et al., 2002; Volosin et al., 2008; Le and Friedman, 2012 ). Since lithium citrate was able to prevent proNGF binding to the p75 NTR -sortilin receptor complex, we evaluated whether treatment with a low dose of lithium was able to attenuate neuronal loss in the hippocampus induced by seizures. Adult male rats were pretreated for 30 min with 6 mg/kg lithium citrate given by intraperitoneal injection, and then given pilocarpine to induce seizures. As previously shown, by 3 d after seizure pilocarpine elicited extensive neuronal death in the hilus and CA1 regions of the hippocampus. Pretreatment with lithium citrate followed by twice daily intraperitoneal injections showed significant neuroprotection in both the hilus (Fig. 4) and CA1 (Fig. 5) , evaluated by counting cells double-labeled for p75
NTR and cleaved caspase-3 (CC3) (Figs. 4A,B, 5A ,B) or double-labeled for p75
NTR and fluorojade C (Figs. 4C, 5C ). The dose of lithium was at least 5-fold lower than doses used in other paradigms of neuroprotection that involved BDNF upregulation (Lauterbach, 2013; Wu et al., 2014) or inhibition of GSK3␤ (Diniz et al., 2013) . We confirmed that this dose of lithium citrate reduced the interaction of p75 NTR and sortilin and did not elicit phosphorylation of GSK3␤ in vivo (Fig. 6) . The dose was also lower than used in the lithium-pilocarpine model of SE, which uses 127 mg/kg lithium (Hillert et al., 2014) compared with 6 mg/kg used here.
Given the many potential actions of lithium ion, it was important to use the lowest effective dose, and to determine the amount of lithium that gains access to the brain. CSF was collected from the cisterna magna of each animal before being euthanized, and assayed for the level of lithium. Since only 50-70 l of CSF can be obtained from each animal, samples were pooled from five rats in each of the four treatment categories for analysis of lithium content. Animals with no injected lithium citrate had minimal levels of lithium detected in the CSF (0.84 ng/ml for controls without pilocarpine, and 1.55 ng/ml for animals with pilocarpine). Rats with no pilocarpine, but with 6 mg/kg lithium citrate injected intraperitoneally had 49.34 ng/ml lithium in the CSF, and rats with pilocarpine-induced seizures and injections of 6 mg/kg lithium had 81.1 ng/ml lithium in the CSF, corresponding to 13 M as an effective neuroprotective dose. This analysis showed that the lithium injected peripherally was able to access the brain, and that this low dose was sufficient to afford neuroprotection.
To determine whether lithium could also afford neuroprotection if provided after the seizures, adult male rats NTR and sortilin. A, E18 hippocampal neurons were cultured for 5 d, biotinylated, and treated for 10 min with proNGF. After stripping remaining surface biotin with glutathione, streptavidin was used to pull down the internalized, biotinylated proteins, which were analyzed by Western blotting for sortilin and p75 NTR . B, Lysates before streptavidin pulldown were also analyzed by Western blotting for sortilin and p75 NTR to assess the input. Densitometric quantification of biotinylated sortilin (C) and p75 NTR (D) from three independent experiments; ‫ء‬different from control at p Ͻ 0.05, ‫ءء‬different from proNGF at p Ͻ 0.05. were treated with lithium citrate delivered intraperitoneally after 1 h of SE, at the time the seizures were terminated with diazepam and phenytoin, followed by twice daily intraperitoneal injections. Even when initially provided after the termination of the seizures, treatment with lithium citrate dramatically reduced the number of apoptotic neurons in both the hilus (Fig. 7) and CA1 (Fig. 8) .
Discussion
Low dose of lithium citrate is neuroprotective in vivo Lithium ion has been used as an effective therapy in many models of disease, particularly as a moodstabilizing drug, as well as to treat brain and spinal cord injury (Young, 2009) , where it can protect neurons from (Dill et al., 2008) . Doses of lithium used in these studies range from the micromolar to millimolar range. At these doses, lithium ion has been shown to have many biological activities that can be neuroprotective (Wada et al., 2005; Young, 2009) . Among the most well-established functions of lithium ion is the phosphorylation and inhibition of GSK3␤ and as well as upregulating levels of BDNF and stimulating antiapoptotic signaling (Rowe and Chuang, 2004; Wada et al., 2005; Young, 2009; Pasquali et al., 2010) . Additionally, lithium ion can promote autophagy, which can be neuroprotective, although this was observed at millimolar doses in vitro (Motoi et al., 2014; Del Grosso et al., 2016; Liu et al., 2017) , and at 50 mg/kg in vivo (Liu et al., 2017) , doses much higher than those used here. Lithium ion has also been shown to delay disease progression of amyotrophic lateral sclerosis (ALS) in humans and in the mouse G93A model of the disease (Fornai et al., 2008) . Since lithium ion can activate so many different neuroprotective signaling pathways, it has many potential therapeutic properties. The effective clinical dose for lithium ion is generally in the range of 0.6-1.0 mM (Young, 2009; Liu et al., 2017 ). In the current study, we demonstrate a neuroprotective effect of lithium citrate from seizureinduced neuronal loss at a dose several orders of magnitude lower than the established clinical range.
In addition to its neuroprotective function, lithium is often used together with pilocarpine to generate a model of epileptic seizures, however the dose of lithium used in that model is a significantly higher [3 mEq (Jope et al., 1986) or 127 mg/kg (Hillert et al., 2014) ] than the protective dose used here (6 mg/kg).
In injury models of TLE, severe continuous seizures defined as SE lead to increased expression and stabilization of proNGF, which binds with selective high affinity to the p75 NTR -sortilin receptor complex and elicits apoptosis (Friedman, 2010). p75 NTR is widely expressed in the CNS during development, but in the adult hippocampus, this receptor is expressed primarily following injury. Previous studies have demonstrated that proNGF and p75 NTR play a major role in mediating neuronal death after SE (Troy et al., 1997; Volosin et al., 2008; Le and Friedman, 2012) , we anticipated that disrupting this association may prevent neuronal death after SE. In these studies, pilocarpine was used to induce seizures. Animals treated with pilocarpine showed increased expression of p75 NTR colocal- NTR . B, Quantification of two independent cohorts expressed as percentage control value which is set at 100%; ‫ءء‬different from control at p Ͻ 0.05, ‫ء‬different from pilo at p Ͻ 0.05. C, Hippocampal lysates were probed for p-GSK3␤ and total GSK3␤. D, Quantification of p-GSK3␤ relative to total GSK3␤ shows no effect of lithium citrate treatment in vivo. Figure 7 . Treatment with lithium citrate after seizures prevents neuronal death in the hilus. Adult male rats were subjected to pilocarpine-induced seizures. Treatment with lithium citrate (6 mg/kg) was initiated after the seizure was terminated and injected twice ized with CC3, the main executor protein in the apoptotic pathway, which was maximal by 3 d after the seizures in the CA1 and dentate hilus regions, consistent with previous studies (Roux et al., 1999; Troy et al., 2002) . Fluorojade C was additionally used to identify dying neurons, and also demonstrated increased double-labeling with p75 NTR after pilocarpine treatment. Pretreatment and twice daily injections with the low dose of lithium (6 mg/ kg) resulted in decreased p75 NTR expression and reduced neuronal death compared to pilocarpine alone, evaluated by CC3 and fluorojade C labeling, in both the CA1 and hilus. Moreover, this treatment elicited a reduction in the association of the p75 NTR -sortilin receptor complex in vivo. The amount of lithium measured in the CSF corresponded to 13 M. As is common for drugs administered in vivo, this amount of lithium is higher than the lowest protective dose shown in vitro, but is well below the usual clinical dose (Young, 2009 ). These results demonstrated that a low dose of lithium can afford neuroprotection from seizure-induced neuronal death. The identification of lithium ion as an inhibitor of proNGF binding to its p75 NTRsortilin receptor complex suggested that this may represent a novel mechanism for neuroprotection.
Since there is a time lag after seizures for the induction of p75
NTR and proNGF to occur before the time of maximal neuronal loss, we evaluated whether lithium citrate would be neuroprotective if provided after SE rather than before the seizures. Rats were therefore given the first dose of lithium when the seizures were terminated with diazepam. In these experiments lithium citrate still afforded significant neuroprotection and reduced cell death in the CA1 and hilus, indicating that lithium citrate can be given after seizures and still prevent neuronal loss. The extent of the time window for neuroprotection after seizures remains to be determined, however being able to provide a neuroprotective agent after the seizure event may be of potential therapeutic value.
We show that lithium citrate has neuroprotective effects in vivo following seizures using doses well below the clinical range used to treat other disorders. The pattern of damage seen in animals treated with both pilocarpine and lithium citrate illustrates that the drug disrupts the well-described pattern of damage following SE. Measurement of lithium levels in the CSF demonstrated that peripherally-injected lithium citrate at this low dose (6 mg/kg) gained access to the brain, and provided a significant protective effect on hippocampal neurons following SE in vivo.
Mechanisms of neuroprotection by lithium
Cultured hippocampal neurons were used to investigate mechanisms by which lithium ion could afford neuroprotection, since Li ϩ is known to prevent neuronal death through multiple pathways (Pasquali et al., 2010) . Lithium ion can induce phosphorylation and inactivation of GSK3␤, a Ser/Thr kinase that is abundant in CNS neurons and promotes cell death by blocking the nuclear translocation of beta catenin. Lithium ion can also induce an increase in BDNF levels (Fukumoto et al., 2001; Wu et al., 2014) , which can promote neuronal survival by activating the TrkB receptor and downstream Akt and Erk signaling. To assess whether lithium citrate may protect neurons by phosphorylation and inactivation of GSK3␤ or by upregulating BDNF expression, we compared the doses of lithium citrate required for protection from proNGF-induced apoptosis with those required for activation of GSK3␤ in cultured neurons and in vivo. We found that the doses of lithium that protected neurons from proNGF-induced death in vitro, or SE-induced death in vivo, were insufficient to elicit phosphorylation of GSK3␤ or upregulation of BDNF, suggesting that neither phosphorylation of GSK3␤ nor induction of BDNF was responsible for preventing neuronal death in these paradigms.
Lithium citrate prevents association and internalization of the p75 NTR -sortilin receptor complex
The original identification of lithium as a potential inhibitor of proNGF-induced neuronal death was based on its ability to prevent binding to the receptor complex, suggesting that the mechanism of protection might be at the level of the membrane receptors. We investigated whether lithium at the neuroprotective nanomolar concentration was effective in blocking either the association of p75 NTR with sortilin, or the internalization of the two receptors following proNGF treatment in culture. Coimmunoprecipitation analysis demonstrated that lithium citrate decreased the association of p75 NTR and sortilin both in vitro and in vivo, thereby reducing formation of the requisite receptor complex for proNGF to induce apoptosis. Using surface biotinylation assays to track the internalization of membrane receptors, we also found that lithium reduced the internalization of p75 NTR and sortilin into the neurons. These data suggest that the neuroprotective effect of lithium citrate at these low doses may be through disrupting the association and internalization of p75 NTR and sortilin and thereby preventing proNGF apoptotic signaling. Although lithium ion can exert neuroprotection through multiple mechanisms, some of the well-established pathways of lithium actions were not activated by this treatment paradigm. Other receptors and pathways are likely to be affected by the lithium citrate treatment as well, however preventing the activation of the p75 NTR -sortilin receptor complex may contribute to the neuroprotective effects.
A previous study demonstrated that the binding of proNGF to the p75 NTR -sortilin receptor complex is stabilized in the presence of calcium (Feng et al., 2010) . It is well established that the prodomain of proNGF is intrinsically disordered, and thus may adopt distinct, transient conformational changes in response to environmental perturbations. Indeed, addition of calcium at physiologic levels enhanced the interaction of the prodomain region with sortilin, and stabilized the formation of a ϳ600 kDa proNGF/sortilin/p75 complex. In contrast, calcium chelation significantly reduced the interaction of proNGF with its receptors. One possible mechanism for the actions of lithium ion may be to alter the conformation of the prodomain region of proNGF, possibly leading to the attenuation of the proNGF-induced p75 NTR -sortilin association and/or internalization, and suggesting a novel mechanism for neuroprotection by lithium ion.
In summary, we demonstrated in this study that low doses of lithium citrate were able to prevent proNGF-induced apoptosis of cultured hippocampal neurons, and provided significant neuroprotection from seizure-induced neuronal loss, even when provided after termination of the seizures. These data suggest a novel therapeutic use for lithium ion to provide neuroprotection from seizures at nanomolar doses, well below the dose currently in clinical use, thereby minimizing potential side effects from the multiple actions of lithium ion that occur at higher micromolar doses.
